Sex-specific differences in systemic immune responses in MIS-C children

Anuradha Rajamanickam1, Nathella Pavan Kumar2, Aishwarya Venkataraman2

  • 1National Institutes of Health-National Institute for Research in Tuberculosis - International Center for Excellence in Research, Chennai, India. anuradha@icerindia.org.

Scientific Reports
|January 19, 2024
PubMed

Insights

Male children with Multisystem Inflammatory Syndrome (MIS-C) exhibit a more robust immune response compared to females. This heightened inflammatory profile in boys may explain sex-based differences in MIS-C disease development and outcomes.

Area of Science:

  • Pediatric Immunology
  • Infectious Diseases
  • COVID-19 Research

Background:

  • Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection.
  • Sex disparities are noted in COVID-19 outcomes, but MIS-C immune responses by sex are understudied.

Purpose of the Study:

  • To investigate sex-specific differences in immune parameters among children diagnosed with MIS-C.
  • To identify immune markers associated with sex in the context of MIS-C.

Main Methods:

  • An observational, cross-sectional study design was employed.
  • Key immune parameters including cytokines, chemokines, acute phase proteins, growth factors, microbial translocation markers, complement components, and matrix metalloproteinases were analyzed in relation to patient sex.

Main Results:

  • Male children with MIS-C showed significantly higher levels of pro-inflammatory cytokines (e.g., IFNγ, IL-6, TNFα), chemokines (e.g., CXCL8, CCL2), acute phase proteins (e.g., CRP), and microbial translocation markers compared to females.
  • Elevated levels of growth factors, complement components, and matrix metalloproteinases were also observed in males.

Conclusions:

  • A heightened immune response, characterized by elevated inflammatory markers, is a distinct feature in male children with MIS-C.
  • These sex-specific immune profiles may contribute to differential disease pathogenesis and clinical outcomes in MIS-C.